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Abstract
Background: Chronic neutrophilic inflammation is a poorly understood feature in a variety of diseases with notable
worldwide morbidity and mortality. We have recently characterized N-acetyl Pro-Gly-Pro (Ac-PGP) as an important
neutrophil (PMN) chemoattractant in chronic inflammation generated from the breakdown of collagen by the actions of
MMP-9. MMP-9 is present in the granules of PMNs and is differentially released during inflammation but whether Ac-PGP
contributes to this ongoing proteolytic activity in chronic neutrophilic inflammation is currently unknown.
Methodology/Principal Findings: Utilizing isolated primary blood PMNs from human donors, we found that Ac-PGP
induces significant release of MMP-9 and concurrently activates the ERK1/2 MAPK pathway. This MMP-9 release is
attenuated by an inhibitor of ERK1/2 MAPK and upstream blockade of CXCR1 and CXCR2 receptors with repertaxin leads to
decreased MMP-9 release and ERK 1/2 MAPK activation. Supernatants obtained from PMNs stimulated by Ac-PGP generate
more Ac-PGP when incubated with intact collagen ex vivo; this effect is inhibited by an ERK1/2 pathway inhibitor. Finally,
clinical samples from individuals with CF demonstrate a notable correlation between Ac-PGP (as measured by liquid
chromatography-tandem mass spectrometry) and MMP-9 levels even when accounting for total PMN burden.
Conclusions/Significance: These data indicate that ECM-derived Ac-PGP could result in a feed-forward cycle by releasing
MMP-9 from activated PMNs through the ligation of CXCR1 and CXCR2 and subsequent activation of the ERK1/2 MAPK,
highlighting for the first time a matrix-derived chemokine (matrikine) augmenting its generation through a discrete
receptor/intracellular signaling pathway. These findings have notable implications to the development unrelenting chronic
PMN inflammation in human disease.
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Introduction
Matrix metalloproteases (MMPs) are members of zinc-depen-
dent proteases responsible for degradation of extracellular matrix
(ECM) components including basement membrane collagen,
interstitial collagen, fibronectin, and various proteoglycans during
normal remodeling and repair processes [1]. This family of
proteolytic enzymes play a role in disease processes including
various hematologic disorders, ocular disease, arthritis, cardiovas-
cular diseases, infectious diseases and cancer [2]. MMP-9
(Gelatinase B, 92-kD type IV collagenase, EC 3.4.24.35) is an
MMP that is present in low quantities in the healthy adult lung,
but much more abundant in several chronic neutrophil (PMN)-
predominant inflammatory lung diseases such as chronic obstruc-
tive pulmonary disease (COPD) and cystic fibrosis (CF). Although
many intrinsic lung cells can be stimulated to produce MMP-9,
inflammatory cells are thought to be the primary source of MMP-
9 in disease [3]. PMNs are thought to play an important role in the
secretion of MMP-9, which is released following stimulation by
inflammatory mediators [4]. Excessive or inappropriate secretion
of MMP-9 may contribute to the pathogenesis of tissue destructive
processes in a wide array of diseases. High levels of MMP-9 related
to the pathogenesis of lung injury have been demonstrated in CF
[5] and COPD patients [6,7,8]. MMP-9 plays an important role in
tissue destruction and inflammation through degradation of matrix
proteins and proteolytic activation of cytokines/chemokines [9].
One family of ligand which plays an important role in
neutrophilic disorders is the cysteine-x-cysteine (CXC) chemokines.
The subfamily of CXC chemokines which are active on PMNs
possess a Glu-Leu-Arg motif and are thus identified as ELR-positive
CXC chemokines; these ligands act on specific CXC receptors on
PMNs (CXCR1 and CXCR2) to induce PMN chemotaxis [10]. In
PLoS ONE | www.plosone.org 1 January 2011 | Volume 6 | Issue 1 | e15781humans, these include interleukin-8 (IL-8) and NAP-2 (active on
CXCR1 and CXCR2 chemokine receptors) and the growth-related
oncogene (GRO)-a, b and c chemokines, which ligate only CXCR2
[11]. IL-8 is a potent PMN chemoattractant and a granulocytosis-
promoting protein [12]. Besides the chemoattractant activity on
PMNs, IL-8 triggers PMNs to release the contents of some of their
granules [13]. Chakrabarty et al. demonstrated that IL-8 binding to
CXCR2 causes the release of MMP-9 from tertiary granules [14]
suggesting that PMN chemoattractants can augment protease
production in disease.
In 1995, Pfister and colleagues demonstrated that alkali
degradation of whole cornea generated two tri-peptides, N-
acetyl-Pro-Gly-Pro (Ac-PGP) and N-methyl-PGP, which are
chemotactic for PMNs and result from hydrolysis of collagen
[15]. Ac-PGP shares both sequence and structural homology with
an important domain of ELR-positive CXC chemokines, and
competitively binds CXC chemokine receptors and requires
CXCR1 and CXCR2 for its PMN chemoattractant activity
[16]. Ac-PGP has been recognized to be a key chemoattractant in
inflammatory diseases and seems to play as important of a role in
PMN influx in chronic inflammatory conditions as traditional
ELR+ CXC chemokines [17] and has recently been reported in
the serum of CF patients [18]. MMP-9 is involved in the
generation of Ac-PGP [19,20], although it is unknown if Ac-PGP
may induce MMP-9 release from PMNs, thereby potentially
augmenting chronic PMN inflammation.
The goal of this study is to determine if Ac-PGP-induced granule
release could result in a feed-forward cycle of inflammation by
causing release of MMP-9, which is required for the ongoing
production of Ac-PGP, and to subsequently reveal the intracellular
signaling pathway involved in PMN activation by Ac-PGP. We find
that Ac-PGP induces MMP-9 release from human PMNs via
CXCR1 and CXCR2 receptor ligation. The activation of
extracellular signal-regulated kinase (ERK)1/2 MAPK is required
for release of MMP-9 by these cells. The impact of the ERK
activation for MMP-9 mediated release is determined by mitigating
MMP-9 release and inhibition of ex-vivo Ac-PGP generation via an
ERK1/2 pathway inhibitor. Finally, clinical samples from individ-
uals with CF, a chronic neutrophilic disorder, demonstrate a strong
correlation in Ac-PGP stimulation and MMP-9, suggesting that this
process may serve as an important switch to a self-propagating
inflammatory state in a myriad of disorders.
Results
Time and dose-dependent increase in MMP-9 activity
from Ac-PGP stimulated human PMNs
Since PMNs are a major cell type responsible for production of
MMP-9, which is required for the generation of Ac-PGP, the
potential role of Ac-PGP in a feed-forward cycle of MMP-9
production was investigated by examining whether Ac-PGP
induces MMP-9 release in PMNs in vitro. Freshly isolated human
PMNs were stimulated for 0, 15, 30, and 45 minutes with 1.0 mg/
ml Ac-PGP and 1.0 mg/ml IL-8. These concentrations were
selected as they reflect the relative potency for neutrophil
chemotaxis for each of these molecules[16]. The cell-free
supernatants were then collected and assayed for the presence of
MMP-9 by gelatin zymography and a specific assay for MMP-9.
We found that Ac-PGP, similar to IL-8, increases gelatinolytic
activity in supernatants of PMNs in a time-dependent manner
(Figure 1A). As shown in Figure 1B, the MMP-9 activity is elevated
in Ac-PGP stimulated PMNs compared to the cells without
stimulation. In addition, a dose-dependent increase in MMP-9
release was observed after Ac-PGP stimulation in both gelatino-
lytic activity (Figure 1C) and MMP-9 activity assay (Figure 1D).
These results suggest that Ac-PGP, generated from the breakdown
of collagen by MMP-9 protease, feeds back to induce MMP-9
release from PMNs to enhance ongoing inflammation.
A specific ERK pathway inhibitor (U0126) blocks MMP-9
release in PMNs stimulated with Ac-PGP
MAPKs are regarded important mediators of a variety of
physiological and pathological cellular processes, including cell
death, cell survival, proliferation, and migration [21]. It has been
reported that IL-8-induced MMP-9 release from PMNs involved
the ERK1/2 kinase signaling pathway [14]. Since Ac-PGP
demonstrated homology and utilizes the same receptors to induce
chemotaxis of PMNs as IL-8, the potential of the MMP-9 release
utilizing an ERK-mediated pathway was examined. To determine
whether phosphorylation of ERK1/2 MAPK was involved in
MMP-9 induction, PMNs were treated with Ac-PGP for 30 min,
and then these cell lysates were analyzed using antibodies specific
for the phosphorylated active forms of ERK1/2 MAPK by
Western blot. As shown in Figure 2A and 2B, there was no
significant difference in the level of total ERK1/2 and b-actin
between protein extracts from PMNs. The levels of phosphory-
lated ERK1/2 were, however, four-fold higher in Ac-PGP
stimulated PMNs compared with unstimulated PMNs. As a
control, Jun N-terminal kinase (JNK) was examined and showed
no difference in ratio of phosphorylated and total JNK with Ac-
PGP stimulation (data not shown). These results suggested that Ac-
PGP induces the activation of ERK1/2 MAPK in PMNs.
Based on the results of ERK1/2 activation (Figure 2A and 2B),
the importance of the ERK1/2 pathway of MMP-9 release was
interrogated utilizing a specific inhibitor for this intracellular
cascade. It was well known that activation of ERK was mediated
through an upstream component of a specific MAPK kinase,
mitogen-activated protein kinase/extracellular signal-regulated
kinase (MEK)1/2. Therefore, activation of ERK was further
investigated using a highly specific MEK1/2 inhibitor, U0126.
Pretreatment with U0126 significantly attenuated Ac-PGP-medi-
ated MMP-9 release, which was demonstrated in both zymo-
graphic analysis (Figure 2C) and MMP-9 activity assay (approx-
imately 66% reduction; P,0.05, as compared with that of Ac-
PGP stimulated PMNs)(Figure 2D), suggesting that a link between
activation of the ERK1/2 MAPK pathway and MMP-9 release
induced by Ac-PGP. As expected, this Ac-PGP-mediated stimu-
lation was accompanied by ERK1/2 phosphorylation and dose-
dependent blockade with U0126 (Figure 2E and 2F). These results
demonstrated the crucial role of ERK1/2 in distinct aspects of the
Ac-PGP mediated MMP-9 release process in PMNs.
Blockade of CXCR1/2 receptor inhibited MMP-9
production in PMNs stimulated with Ac-PGP
Ac-PGP competitively binds CXC chemokine receptors and
CXCR1 and CXCR2 ligation is required for its PMN chemotactic
activity [16]. To determine the importance of the CXCR1 and
CXCR2 receptor on the Ac-PGP mediated MMP-9 induction from
PMNs, repertaxin (an inhibitor of CXCR1 and CXCR2) was used.
Pretreatment of PMNs with repertaxin suppressed MMP-9 release
from PMNs as shown in zymographic analysis (Figure 3A) and MMP-9
activity assay (Figure 3B). In order to demonstrate the importance of
CXCR1 and CXCR2 signaling on ERK activation, PMNs (either
stimulated with Ac-PGP or blocked with repertaxin)were examined for
phospho- and total ERK expression. Figure 3C and 3D demonstrate
that repertaxin blockade mitigates ERK phosphorylation, highlighting
an important link between cell surface receptor activation and a
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PLoS ONE | www.plosone.org 2 January 2011 | Volume 6 | Issue 1 | e15781Figure 1. Increased MMP-9 activity in culture supernatants from human PMNs stimulated with Ac-PGP. Human PMNs isolated from
peripheral blood were stimulated with Ac-PGP and IL-8 for different times and then supernatants were collected for MMP-9 assay. A. The detection of
gelatinolytic activity in a time-dependent manner by gelatin zymography representative of three gels. B. The quantification of specific MMP-9 activity
in a time-dependent manner by ELISA-based assay. C. The detection of gelatinolytic activity in a dose-dependent manner by gelatin zymography
representative of three gels. D. The quantification of MMP-9 activity in a dose-dependent manner by ELISA-based assay. *p,0.05, compared with
PMN only within same time point.
doi:10.1371/journal.pone.0015781.g001
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PLoS ONE | www.plosone.org 3 January 2011 | Volume 6 | Issue 1 | e15781Figure 2. The effect of ERK1/2 MAPK inhibitor on the Ac-PGP mediated MMP-9 release in PMNs. PMNs were pretreated with ERK1/2
MAPK inhibitor U0126 or vehicle for 30 minutes, and then stimulated with Ac-PGP (1.0 mg/ml) for 30 minutes. Cell-free supernatants were collected
for MMP-9 assay. The levels of ERK1/2 MAPK were determined by western blot analysis of lysates from stimulated PMNs with actin controls which
paralleled total ERK 1/2. Phosphorylated ERK was determined using an anti-ERK antibody that recognizes phosphorylated threonine and tyrosine
residues (Thr202/Tyr204). A. Total and phosphorylated level of ERK1/2 MAPK representative of three gels. B. Fold change of phosphorylation of ERK1/
2 MAPK versus total ERK1/2 MAPK normalized to PMN control. C. The detection of gelatinolytic activity by gelatin zymography representative of three
gels. D. The quantification of specific MMP-9 activity by ELISA-based assay. E. Total and phosphorylated level of ERK1/2 MAPK representative of three
gels. F. Fold change of phosphorylation of ERK1/2 MAPK versus total ERK1/2 MAPK normalized to PMN control. *p,0.05 compared to Ac-PGP without
inhibitor pretreatment.
doi:10.1371/journal.pone.0015781.g002
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These results suggested that Ac-PGP-induced MMP-9 release occurs
via a CXCR-ERK activation signal pathways.
Heavy labeled Ac-PGP produced collagen-derived
Ac-PGP via an ERK-dependent pathway
Since Ac-PGP has the ability to release MMP-9 from primary
blood PMNs and MMP-9 is central to Ac-PGP generation,
supernatants from Ac-PGP stimulated PMNs were studied to
determine if they could generate de-novo Ac-PGP from intact
collagen. In order to answer this question, a C
13 N
15 labeled Ac-
PGP (with the heavy label placed on both prolines) was
synthesized to distinguish it from Ac-PGP generated endogenously
from collagen (Figure 4A). Spectra from Ac-PGP demonstrates a
total peptide mass of 312, with daughter ions of 112 and 140
(Figure 4A, left panel); Spectra for C
13N
15 Ac-PGP show a peptide
Figure 3. The effect of CXCR1 and CXCR2 inhibitor on the Ac-PGP mediated MMP-9 release in PMNs. PMNs were pretreated with the
CXCR1 and CXCR2 inhibitor repertaxin at different dose for 20 minutes and then stimulated with Ac-PGP (1.0 mg/ml) for 30 minutes. Cell-free
supernatants were collected for MMP-9 assay. The levels of ERK1/2 MAPK activation were determined by western blot analysis of lysates from
stimulated PMNs with actin controls which paralleled total ERK 1/2. Phosphorylated ERK1/2 MAPK was determined using the anti-ERK antibody that
recognizes phosphorylated threonine and tyrosine residues (Thr202/Tyr204). A. The detection of gelatinolytic activity by gelatin zymography
representative of three gels. B. The quantification of MMP-9 activity by ELISA-based assay. C. Total and phosphorylated level of ERK1/2 MAPK
representative of three gels D. Fold change of phosphorylation of ERK1/2 MAPK versus total ERK1/2 MAPK normalized to PMN control. *p,0.05
compared to Ac-PGP without inhibitor pretreatment.
doi:10.1371/journal.pone.0015781.g003
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panel). To determine if this heavy-labeled Ac-PGP (denoted as Ac-
P*GP*) could release MMP-9 from PMNs, primary blood PMNs
were stimulated with Ac-P*GP* and showed a similar increase in
gelatinolytic bands with dose-dependent stimulation as unlabeled
Ac-PGP (Figure 4B). Finally, supernatants from Ac-P*GP*
stimulated PMNs generated increased endogenous Ac-PGP
from collagen and this effect was mitigated by the pre-treatment
of the U0126 inhibitor (Figure 4C). These findings further
demonstrated the importance of ERK-mediated pathways in Ac-
PGP generation and suggested important regulatory roles in
human disease.
Figure 4. The blockade of ERK1/2 MAPK activation inhibited Ac-PGP production. Human peripheral blood PMNs (5.25610
5) were
pretreated with U0126 (10 and 20 mM) versus vehicle for 30 minutes and then incubated for 30 minutes with labeled Ac-PGP. The supernatants
collected from incubated cells were placed on type I collagen (1.0 mg/ml) for 24 hours at 37uC. Ac-PGP and C
13N
15 labeled Ac-PGP were analyzing by
ESI-LC-MS/MS. Ac-PGP values of the samples on PBS were subtracted from Ac-PGP values of samples incubated on type I collagen to determine Ac-
PGP production. A. Detection of Ac-PGP and C
13N
15 Ac-PGP via mass spectrometry. B. The detection of gelatinolytic activity in culture supernatants
from human PMNs stimulated with labeled Ac-PGP by gelatin zymography representative of three gels. C. The measurement of Ac-PGP production by
ESI-LC-MS/MS. The bar graph represents the percent of relative Ac-PGP production normalized to labeled Ac-PGP control. *p,0.05 compared to
labeled Ac-PGP without inhibitor pretreatment, n=4 wells/condition.
doi:10.1371/journal.pone.0015781.g004
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MMP-9 and elevated numbers of PMNs
It has been reported that there are increased levels of Ac-PGP in
CF [19] and COPD [8] sputum suggesting an important role of
this peptide in conditions with prominent ECM remodeling and
neutrophilic inflammation. To determine whether Ac-PGP may
be playing a role in MMP-9 release from PMNs in vivo,w e
attempted to analyze the correlations between Ac-PGP and high
levels of MMP-9 in the CF lower airway. Sputum from 14 patients
with inpatient CF exacerbation (average forced expiratory volume
1 second (FEV1) =39% (+/224.1); 56%: delta F508 homozy-
gotes, 22%: delta F508 heterozygotes, 22%:other genotype) were
collected and analyzed for both MMP-9 and Ac-PGP peptides.
Clinical data for this population is presented in Table 1.
Zymography was done on samples (Figure 5A) showing notable
but variable gelatinolytic activity in the samples. The samples were
then assessed for a potential regulatory relationship between Ac-
PGP and MMP-9 release in human disease. In order to control for
the total PMN burden in a given sample as a confounder for
increased MMP-9 expression, myeloperoxide (MPO), a marker of
PMN influx, was measured. Figure 5B demonstrates that even
when MMP-9 is controlled for by MPO, there is a notable
correlation between Ac-PGP levels and MMP-9. These results
demonstrate a strong correlation (r=0.63, p=0.017) in CF
clinical samples between concentration of Ac-PGP and the level
of MMP-9, recapitulating with fidelity our ex vivo and in vitro data.
Discussion
An important question in the field of inflammatory biology is
how a self-limited, acute neutrophilic inflammatory pathway in
response to a specific stimulus can become a self-propagating,
chronic inflammatory response when the initial inciting event is
often resolved [22]. While chemokine pathways are thought to
play an important role in the initial inflammatory response seen to
stimuli, their role in a persistent neutrophilic inflammatory state is
not well-defined. This apparent disparity in the roles of preformed
chemokine mediators in acute and chronic neutrophilia has led
many to hypothesize that there are other discrete pathways
involved in chronic neutrophilic inflammatory response. Our
initial description of Ac-PGP highlighted this novel fragment’s
capability to cause PMN chemotaxis by ligation of CXC receptors
[16]. Despite this exciting finding of a non-cognate ligand for
CXC receptors residing in the extracellular matrix (ECM), it did
not explain how this matrikine could serve to induce a shift from
an acute to chronic neutrophilic inflammatory phenotype.
In a previous study, we demonstrate that the release of MMP-9
into the airway leads to the cleavage of collagen fragments, leading
to Ac-PGP generation. MMP-9 is a protease that degrades
extracellular matrix proteins including gelatin, collagen, elastin,
and laminin [14,23] and plays important roles in tissue destruction
and also in tissue remodeling and inflammation [24]. Recent
evidence suggests that although PGP is present in human disease
specimens, autoantibodies directed at the fragments are not
observed [25]. Here, for the first time, we describe how Ac-PGP
can stimulate primary peripheral blood PMNs and induce the
release of MMP-9 from PMN tertiary granules. This effect is
observed in a time dependent manner, examining MMP-9 activity
(Figure 1A) and quantity of MMP-9 (Figure 1B) from 15 to 45
minutes of Ac-PGP stimulation. In addition, a dose-dependent
increase in both MMP-9 activity (Figure 1C) and quantity
(Figure 1D) was observed over a three-log increase in Ac-PGP
concentration. These findings highlight that, similar to IL-8, Ac-
PGP can act to induce MMP-9 release in a specific, coordinated
manner from PMNs.
MMP-9 has been observed to be differentially regulated during
situations of acute versus chronic neutrophilic responses [26].
Previous evidence has shown that various intracellular pathways
may be important in the regulation of MMP-9 expression during
inflammation. Several lines of evidence have shown that MMP-9
gene expression is regulated by the p42/p44 MAPK, p38 MAPK,
and JNK in different cell types [27,28,29,30,31]. Indeed, the
Table 1. Clinical Data of CF Subjects.
Sample Gender
Age
years Genotype Bacteriology
FEV1
%
FVC
%
FEF
(25–75%)
1 M 26 DeltaF508/17171G-.AP A
+ 22 34 9
2 F 34 DeltaF508/DeltaF508 PA
+ 39 52 19
3 M 23 Unknown/E60X PA
+ 21 44 9
4 M 32 Unknown/Unknown SA
+,PA
+ 19 26 7
5 M 20 DeltaF508/DeltaF508 PA
+ 34 60 8
6 F 11 DeltaF508/DeltaF508 PA
+ 104 100 102
7 F 23 DeltaF508/DeltaF508 SA
+ 60 56 57
8 M 30 Unknown/DeltaF508 PA
+ 37 43 21
9 M 20 DeltaF508/DeltaF508 PA
+ 25 36 10
10 F 33 DeltaF508/3849+10KBC-.TS A
+,P A
+,few AX 24 31 14
11 M 34 DeltaF508/DeltaF508 SA
+,PA
+ 34 49 31
12 M 31 DeltaF508/DeltaF508 SA
+,PA
+ 28 42 9
13 F 23 DeltaF508/DeltaF508 SA
+ 71 69 60
14 M 20 Unknown/Unknown SA
+,PA
+ 24 43 6
N=14 36% females
64% males
2566.9 (M6SD) 56% Delta F508 homozygous
22% Delta F508 heterozygous
22% other or unidentified
50% PA
+ only
14% SA
+ only
36% PA
+ &S A
+
38624.1
(M6SD)
49618.8
(M6SD)
26628.2
(M6SD)
doi:10.1371/journal.pone.0015781.t001
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and degranulation in many cell types [32,33,34]. Human PMNs
express ERK1/2, JNK, and p38 MAPKs [35,36], and ERK1/2 is
activated following stimulation with IL-8 [37]. Activation of
ERK1/2 regulates various effects in PMNs and other granulocytes
including release of granule contents by degranulation [38,39]. In
the present studies, we demonstrate that activation of the ERK1/2
MAPK pathway is necessary for MMP-9 release by PMNs in
response to Ac-PGP. This is supported by the finding that Ac-PGP
specifically phosphorylated and activated the ERK1/2 MAPK
pathway (Figure 2A and 2B). This ERK1/2 activation seen
intracellularly from Ac-PGP stimulated PMNs corresponds with
increases in MMP-9 activity (Figure 2C) and quantity (Figure 2D)
from supernatants, suggesting a potential link between Ac-
PGP,ERK1/2, and MMP-9 release. To confirm the central
importance of the ERK1/2 MAPK pathway in MMP-9 release, a
specific cell-permeant ERK1/2 inhibitor, U0126, is utilized and
successfully blocked intracellular ERK phosphorylation (Figure 2E
and 2F) and Ac-PGP-induced MMP-9 release in PMNs, in a dose-
dependent manner (Figure 2C and 2D) confirming that Ac-PGP
induces the release of MMP-9 from PMNs through an ERK
MAPK pathway.
Since the blockade of CXCR1 and CXCR2 receptors can
suppress the degranulation of PMNs induced by different
chemokines and cytokines [14,40,41] and Ac-PGP acts through
CXCR1 and CXCR2-dependent mechanisms to attract PMNs to
inflammatory sites [16], we also examined the impact of CXC
blockade on the MMP-9 release axis. The ERK1/2-mediated
release of MMP-9 from PMNs (Figure 3A and 3B) and
intracellular ERK1/2 phosphorylation (Figure 3C and 3D) are
significantly abrogated when repertaxin, a CXCR1 and CXCR2
specific inhibitor, was utilized. Collectively, these findings indicate
a crucial inflammatory connection of external receptor activation
and internal signaling through an Ac-PGP-CXCR-ERK1/2-
MMP-9 pathway, strongly suggesting a novel feed-forward
pathway to augment Ac-PGP production.
A recent article has suggested the possibility that Ac-PGP does
not directly interact with CXC receptors on PMNs to cause
chemotaxis [42]. This was in large measure due to this group’s
inability to demonstrate competition of Ac-PGP with radiolabeled
IL-8 in a CXCR radioreceptor assay. In all likelihood, this effect
was observed due to not preincubating a low affinity CXCR ligand
(Ac-PGP) with PMNs prior to incubation with the higher affinity
ligand (IL-8) in the radioreceptor assay. In addition, these authors
claim that Ac-PGP does not activate G-proteins but it is difficult
for us to see how this would be possible since Ac-PGP is clearly
chemotactic for PMNs as demonstrated in this group’s manuscript
as well as others [16,19,42,43] and PMN chemotaxis is mediated
through G-protein coupled receptors and activation of G-proteins.
Figure 4 demonstrates that, by utilizing a heavy-labeled Ac-PGP
as a PMN stimulus, Ac-PGP can be generated in an ex vivo assay
and this effect is blocked by the ERK1/2-specific inhibitor thereby
definitively showing that Ac-PGP has the capability to induce its
own generation through a PMN-mediated pathway. This pathway
may play an important role in augmentation of ongoing
neutrophilic inflammation observed in chronic inflammatory
conditions. Our group has previously demonstrated that individ-
uals without known lung disease have very low MMP-9 activity,
Ac-PGP levels, and PMN burden [5,19] suggesting that there may
be dysregulation of important protease-mediated inflammatory
mechanisms in chronic neutrophil-predominant lung disorders
such as CF. To examine this possibility, sputum samples from CF
patients were examined for Ac-PGP content and MMP-9 content
in the hopes of finding a potential correlation in a chronic PMN –
predominant human disease. Since MMP-9 levels may be
increased solely by the presence of increased PMN burden in
the clinical sample, the MMP-9 level is controlled for by the MPO
levels (a validated surrogate marker for PMN influx) in the clinical
Figure 5. Ac-PGP correlated to the MMP-9/MPO ratio in CF patients. CF (n=14) sputum samples were collected to determine gelatinolytic
activity by gelatin zymography (each lane represents an individual patient) (A) and for the measurement of Ac-PGP, MPO and MMP-9, and correlation
analysis was conducted between Ac-PGP and MMP-9/MPO ratio (B). The CF sputum samples demonstrated a correlation coefficient (r) of 0.63
(p=0.017).
doi:10.1371/journal.pone.0015781.g005
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correlation (r=0.63, p=0.017) is observed between MMP-9 and
Ac-PGP strongly suggesting that the regulatory relationship
observed in the experimental models may also be important in a
chronic inflammatory disorder.
To our knowledge, this work represents the first data
demonstrating that a matrikine (such as Ac-PGP) has the capacity
to induce its own generation, thereby augmenting an inflamma-
tory response. Based on the observations from our previous studies
and current findings, a notable ‘‘feed-forward’’ model of Ac-PGP
inflammation is very apparent. It is possible that recruited PMNs
from blood may bind either chemokines or Ac-PGP via CXCR1
and CXCR2, leading to intracellular ERK activation and
subsequent MMP-9 release. MMP-9 then leads to ongoing
collagen hydrolysis with Ac-PGP production. This pathway forms
a positive feed-forward loop between Ac-PGP, PMNs, and MMP-
9 (Figure 6). As such, there are numerous potential therapeutic
targets in this system of chronic neutrophilic inflammation;
perhaps the most appealing is blocking generation of Ac-PGP by
inhibition of MMP-9 either in the extracellular environment or by
prevention of release through targeting CXC receptors. Recently,
our group has also shown that PGP has an endogenous anti-
inflammatory pathway mediated by leukotriene A4 hydrolase and
regulating this enzyme may also offer a unique treatment pathway
[44]. Currently, our laboratory is actively pursuing compounds
which focus on these and other regulatory pathways in the
generation of chronic neutrophilic inflammation.
Materials and Methods
Patient Populations and Sputum Collection
All human studies were approved by the UAB Institutional
Review Board. CF patients were recruited from the UAB Gregory
Fleming James Cystic Fibrosis Center. All subjects carried the
diagnosis of CF based on accepted diagnostic criteria [45]. All
subjects provided written informed consent. Samples and health
information were labeled using unique identifiers to protect subject
confidentiality. Sputum samples were spontaneously expectorated
by subjects. Sputum samples were collected on ice, diluted 1:1 with
1X PBS, centrifuged at 1000 rpm for 15 min, and supernatants
were stored at -80uC for later analysis.
Reagents
Ac-PGP was synthesized by Anaspec Inc., (San Jose, USA).
RIPA lysis buffer, PMSF, Sodium Orthovanadate, Albumin from
bovine serum (cohn fraction V) are from Santa Cruz (Santa Cruz,
CA USA). Ficoll-Paque was from GE Healthcare Bio-Sciences
Inc., (Montre ´al, Canada). HBSS without phenol was from
Mediatech, Inc. (Hernden, VA). Rabbit anti-human ERK1/2
antibody, rabbit anti-phospho-human ERK1/2 antibody
(DB.14.4E), rabbit anti-human total and phospo-JNK antibodies,
goat anti-rabbit coupled to HRP, and U0126 were purchased
from Cell Signaling Technologies (Beverly, MA, USA). Chemilu-
minescence staining kit was from Millipore Corp. (Billerica, MA,
USA). MMP-9 -specific ELISA kits and recombinant human (rh)
IL-8 were purchased from R&D Systems Inc. (Minneapolis, MN,
USA). MPO kits were purchased from Calbiochem (San Diego,
CA, USA). b-actin antibody (Clone Ac-15), type I collagen, and
gelatin was purchased from Sigma-Aldrich (St. Louis, MO, USA).
Treatment of PMNs with Ac-PGP
For blood PMNs preparation, venous blood was separated on
Ficoll (1.119 g/ml, bottom) and Ficoll-Paque (1.077 g/ml, top)
layers to separate the granulocytes from the mononuclear
leukocytes. The granulocyte pellet was washed in HBSS two
times and then resuspended in HBSS containing 1% BSA (w/v).
The purity of PMN preparations were 95% via staining and flow
cytometry.
The prewarmed PMN suspensions (37uC, 3.5610
6 cells/ml)
were incubated in 1% BSA/HBSS with or without Ac-PGP (0.01–
1.0 mg/ml) or IL-8 (1.0 mg/ml) for different time intervals at 37uC
in 5% CO2. For all treatment conditions described in these
experiments and all time points studied, PMN viability was
assessed by trypan blue exclusion in all conditions, doses, and time
points, and the PMN viability was .97%, which correlated with
cell viability observed for time periods less than 2 hours ex vivo
[46]. The level of gelatinolytic enzymes released in cell-free
supernatant was measured by gelatin zymography and the MMP-9
activity in cell-free supernatant was measured by an ELISA-based
assay. For the analysis of MMP-9 release inhibition, the
prewarmed PMN suspensions were treated for 20 to 30 minutes
with the inhibitors (or vehicle) at the indicated concentrations (see
figure legends), followed by an incubation with or without Ac-PGP
(1.0 mg/ml) for 30 minutes at 37uCi n5 %C O 2. Cell-free
supernatant were then harvested for gelatinolytic enzymes release
and MMP-9 assay.
Zymography
Porcine skin gelatin at 1.0 mg/ml was added to a 7.5% SDS-
polyacrylamide solution before casting. The samples were diluted
in nonreducing sample buffer, and 25 ml of sample was added to
each lane. All samples are electrophoresed at 45 V for 5 h at 4uC.
Following electrophoresis, gels were washed in 2.5% Triton X-100
for 30 minutes at 25uC, and then incubated in 50 mM Tris and
5.0 mM CaCl (pH=8.0) for 16 h at 37uC. Gels were stained in
0.05% Coomassie blue for 30 min and subsequently distained in
acetic acid and methanol for optimal exposure. Higher molecular
weight bands on gelatin zymograms likely represented MMP-9/
NGAL complexes.
MMP-9 activity assay
MMP-9-specific ELISA-based activity assays were used to
quantify specific MMP activity. Both samples and recombinant
enzyme standards were prepared and incubated for 2 h at room
temperature in 96-well plates coated with a mAb for MMP-9.
After incubation, samples and standards were activated with
1.0 mM 4-aminophenylmercuric acetate (APMA), a chemical
activator of MMPs, and further incubated for 2 h at 37uC. After
incubation, a fluorogenic substrate (Fluor-Pro-Leu-Gly-Leu-Ala-
Arg-NH2) was placed in each well and the plate was incubated at
37uC for 18 h. The plate was then read on a spectrophotometer
(excitation and emission wavelength of 320 and 405, respectively,
SpectraMax Gemini; Molecular Devices) and data were quantified
using standard curves provided with the kits. The wells not treated
with APMA represent the pro-MMP-9 level in the sample whereas
the matched wells treated with APMA represent the total MMP-9
level (pro+activated) in the sample.
Myeloperoxidase (MPO) assay
The CalbiochemH InnoZymeTM Myeloperoxidase Activity Kit
was used to quantify specific active human MPO. Both samples
and MPO standards were prepared and incubated for 1 h at room
temperature with gentle shaking in 96-well plates coated with
polyclonal antibody specific for human MPO. After four washes,
detection reagent that included TMB and hydrogen peroxide was
added for 30 minute incubation at 37uC. Following color
development, the reaction was stopped with sulfuric acid and
the absorbance of the oxidized TMB is detected at 450 nm. The
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Analysis of ERK-1/2 MAPK activation by Western blot
PMNs were incubated with Ac-PGP (1.0 mg/ml) for 30
minutes. To evaluate the efficacy of the ERK pathway inhibitor,
U0126, to inhibit ERK1/2 phosphorylation and activation, PMNs
were treated with the indicated concentrations of inhibitor in 1%
BSA/HBSS for 30 min, followed by incubation with or without
Ac-PGP (1.0 mg/ml) for 30 min. The samples were centrifuged,
and the cell pellets were disrupted in cold (4uC) RIPA lysis buffer.
After 30 min incubation on ice, the lysates were centrifuged to
Figure 6. A model of persistent matrikine production and neutrophilic inflammation. During chronic PMN inflammation, collagen is
hydrolyzed releasing Ac-PGP causing ongoing neutrophilic influx (A). In addition to causing PMN influx, Ac-PGP ligation of CXCR1 and CXCR2 leads to
intracellular ERK phosphorylation and activation (B) and degranulation of MMP-9 from PMN tertiary granules (C and D). This MMP-9 acts on exposed
collagen leading to Ac-PGP generation (E) and a feed-forward inflammatory response on PMNs (F).
doi:10.1371/journal.pone.0015781.g006
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5 min in Laemmli buffer. Samples (15 mg total protein/lane,
unless otherwise stated) were then electrophoresed through 10%
SDS-polyacrylamide gels and were transferred onto nitrocellular
membranes, which were blocked in TBST (pH 7.4) containing 5%
BSA for 1 h and probed with 1:2000 anti-phospho-ERK-1/2 or
anti-ERK-1/2, followed by the appropriate secondary antibody
coupled to HRP (1:5,000; Cell Signaling Technology, Beverly,
MA, USA). Immunoblots were then developed using ECL
chemiluminescent kits. Densitometric analyses were performed
using NIH Imaging software.
Electrospray ionization-liquid chromatrography-mass
spec/mass spec (ESI-LC-MS/MS)
Ac-PGP and Ac-P*GP* were measured using a MDS Sciex
(Applied Biosystems, Foster City, CA) API-4000 spectrometer
equipped with a Shimadzu HPLC (Columbia, MD). HPLC was
conducted using a 2.06150 mm Jupiter 4u Proteo column
(Phenomenex, Torrance, CA) with A: 0.1% HCOOH and B:
MeCN +0.1% HCOOH: 0 min-0.5 min 5% buffer B/95% buffer
A, then increased over 0.5–2.5 min to 100% buffer B/0% buffer
A. Background was removed by flushing with 100% isopropanol/
0.1% formic acid. Positive electrospray mass transitions occured at
312-140 and 312-112 for Ac-PGP and 324-146 and 324-117 for
Ac-P*GP*.
Ex Vivo Collagen Assay
Type I collagen (1.0 mg/ml) was solubilized by wetting with
glacial acetic acid and diluting to volume with water (final
pH,4.5), and rotated until complete dissolved. This solution was
then extensively dialyzed against distilled water (pH adjusted to 3.5
by addition of acetic acid). 40 ml of cell-free supernatants were
incubated with 40 ml of dialyzed intact type I collagen for 24 h at
37uC and 5% CO2 with exogenous prolyl endopeptidase (2.5 mg/
ml). After incubation, samples were filtered through a 10-kDa filter
(Millipore Corporation, Billerica, MA), the filters were washed
with 40 ml of 1.0 mM HCl. The solutions were analyzed by
multiple reaction monitoring (MRM) using ESI- LC-MS for levels
of Ac-PGP. Amounts of Ac-PGP generated by each cell-free
supernatant sample from collagen were determined by comparison
with cell-free supernatant incubated with PBS.
Statistical analyses
Descriptive statistics including mean and SD were conducted
for all quantitative measures. The two-tailed Student t test was
used for comparisons between two groups and ANOVA was used
for comparing means of three or more groups. Spearman
correlation was used to compare the relationship between Ac-
PGP levels and MMP-9/MPO levels. The results were considered
significant if p values were 0.05 or less.
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